Magnostics Ltd is a bionanotechnology SME that has been founded on successive research investments from NASA and the Irish Research Counsel. We have developed a highly specific screening assay for Acute Mesenteric Ischemia and the high performance AurosphereTM magnetic nanoparticles, which enable rapid, efficient separations of proteins, nucleic acids, and cells.
Acute Mesenteric Ischemia (AMI)
AMI is a deadly, hard-to-detect condition that will impact 88 thousand patients this year in EU, UK, USA, Canada, and Asia. This disease results in 60%-80% mortality within the first 24 hours, and every 30 minutes of delay increases the mortality rate by about 5%. Surgeons and emergency care physicians are waiting for a specific and sensitive screening assay to complement X-ray computed tomography.
Research and Development
AurosphereTM nanoparticles increase the rate and efficiency of separation of specific biomarkers through coatings with advanced chemistries. In collaboration with our medical partners we have developed a novel screening assay for Acute Mesenteric Ischemia that promises to improved the quality of care for this rare but deadly disease. This screening test could save up to 75% of AMI patients if it is deployed in an emergency care clinical laboratory.
Magnostics supplies the AurosphereTM nanoparticles to the biotechnology industry for in vitro diagnostics (IVD), bioseparations and high throughput screening (HTS). We seek medical and business partnerships for commercialization of our AMI screening test. Magnostics is an ISO13485 compliant supplier of magnetic beads for diagnostic and bioseparation kits.